Geoffrey Biegler

Cooley advised Eccogene on its strategic collaboration and license agreement with AstraZeneca, a global biopharmaceutical company. Eccogene will receive an initial upfront payment of $185 million and will also be eligible to receive up to $1.825 billion in future clinical, regulatory and commercial milestones, as well as royalty payments.

Cooley is representing NeuroDerm and its parent company, Mitsubishi Tanabe Pharma Corp., in a post-grant review challenging an AbbVie patent related to methods of continuous subcutaneous treatment of Parkinson’s disease. After a hearing in October 2023, the US Patent Trial and Appeal Board issued a final written decision finding all claims of AbbVie’s patent unpatentable.

NeuroDerm and AbbVie are both seeking regulatory approval in the US for continuous subcutaneous treatments for Parkinson’s disease, and AbbVie’s patent effectively attempted to claim all successful methods of such treatment. Lawyers Geoff Biegler and Mark Weinstein are leading the team representing NeuroDerm with assistance from associates, Bonnie Fletcher Price and Andrew Lau.